Italy

Italy

Hepatitis B

Download HBV data

Prevalence of chronic HBV (HBsAg+)

National
Download
Value (%) Year Type Source
0.71 (0.62 - 0.80) 2019 Modelled IHME
0.71 (0.62 - 0.80) 2018 Modelled IHME
0.72 (0.62 - 0.80) 2017 Modelled IHME
0.74 (0.64 - 0.82) 2016 Modelled IHME
0.76 (0.67 - 0.85) 2015 Modelled IHME
0.78 (0.69 - 0.87) 2014 Modelled IHME
0.8 (0.71 - 0.89) 2013 Modelled IHME
0.82 (0.72 - 0.91) 2012 Modelled IHME
0.83 (0.74 - 0.92) 2011 Modelled IHME
0.85 (0.75 - 0.95) 2010 Modelled IHME
0.87 (0.77 - 0.96) 2009 Modelled IHME
0.89 (0.80 - 0.99) 2008 Modelled IHME
0.91 (0.81 - 1.01) 2007 Modelled IHME
0.93 (0.83 - 1.03) 2006 Modelled IHME
0.95 (0.85 - 1.05) 2005 Modelled IHME
0.96 (0.86 - 1.06) 2004 Modelled IHME
0.98 (0.87 - 1.08) 2003 Modelled IHME
0.99 (0.89 - 1.09) 2002 Modelled IHME
1 (0.90 - 1.11) 2001 Modelled IHME
1.02 (0.92 - 1.13) 2000 Modelled IHME
1.04 (0.93 - 1.15) 1999 Modelled IHME
1.06 (0.96 - 1.17) 1998 Modelled IHME
1.09 (0.98 - 1.19) 1997 Modelled IHME
1.11 (1.01 - 1.22) 1996 Modelled IHME
1.14 (1.03 - 1.24) 1995 Modelled IHME
1.16 (1.05 - 1.27) 1994 Modelled IHME
1.18 (1.06 - 1.30) 1993 Modelled IHME
1.2 (1.08 - 1.32) 1992 Modelled IHME
1.22 (1.10 - 1.35) 1991 Modelled IHME
1.24 (1.11 - 1.38) 1990 Modelled IHME
0.7 (0.40 - 1) 2016 Modelled ECDC
0.5 (0.30 - 1) 2007 Survey/reported Cozzolongo R et al, 2009
0.8 (0.40 - 1.30) 2003 Survey/reported Pendino GM, 2005
0.7 (0 - 3.90) 2001 Survey/reported Floreani A, 2006
1.7 (0.90 - 2.90) 2014 Survey/reported Morisco, 2017
1.67 (1.26 - 2.17) 2015 Modelled WHO
Showing out of
Show more
Children under-5 years
Download
Value (%) Year Type Source
0.03 (0.02 - 0.03) 2019 Modelled IHME
0.03 (0.02 - 0.03) 2018 Modelled IHME
0.03 (0.02 - 0.03) 2017 Modelled IHME
0.03 (0.02 - 0.03) 2016 Modelled IHME
0.03 (0.02 - 0.03) 2015 Modelled IHME
0.03 (0.02 - 0.03) 2014 Modelled IHME
0.03 (0.02 - 0.03) 2013 Modelled IHME
0.03 (0.02 - 0.03) 2012 Modelled IHME
0.03 (0.02 - 0.03) 2011 Modelled IHME
0.03 (0.02 - 0.03) 2010 Modelled IHME
0.03 (0.02 - 0.03) 2009 Modelled IHME
0.03 (0.02 - 0.03) 2008 Modelled IHME
0.03 (0.02 - 0.04) 2007 Modelled IHME
0.03 (0.02 - 0.04) 2006 Modelled IHME
0.03 (0.02 - 0.04) 2005 Modelled IHME
0.03 (0.02 - 0.04) 2004 Modelled IHME
0.03 (0.02 - 0.04) 2003 Modelled IHME
0.03 (0.02 - 0.04) 2002 Modelled IHME
0.03 (0.02 - 0.04) 2001 Modelled IHME
0.03 (0.03 - 0.04) 2000 Modelled IHME
0.04 (0.03 - 0.05) 1999 Modelled IHME
0.04 (0.03 - 0.06) 1998 Modelled IHME
0.05 (0.04 - 0.06) 1997 Modelled IHME
0.06 (0.05 - 0.07) 1996 Modelled IHME
0.07 (0.05 - 0.09) 1995 Modelled IHME
0.08 (0.06 - 0.10) 1994 Modelled IHME
0.1 (0.08 - 0.13) 1993 Modelled IHME
0.13 (0.10 - 0.16) 1992 Modelled IHME
0.16 (0.12 - 0.20) 1991 Modelled IHME
0.19 (0.14 - 0.24) 1990 Modelled IHME
0.61 (0.39 - 0.93) 2015 Modelled WHO
Showing out of
Show more
Pregnant women
Download
Value (%) Year Type Source
0.8 (0.70 - 1) 2016 Modelled ECDC
0.9 (0.70 - 1) 2009 Survey/reported Spada E et al, 2014
0.8 (0.60 - 1) 2012 Survey/reported Ruffini E et al, 2014
Showing out of
Show more
Prisoners
Download
Value (%) Year Type Source
6.7 (5.20 - 8.40) 2002 Survey/reported Babudieri S et al, 2005

HBV-related death rate

National
Download
Value (per 100,000) Year Type Source
2.84 (2.52 - 3.19) 2019 Modelled IHME
2.77 (2.46 - 3.12) 2018 Modelled IHME
2.7 (2.39 - 3.03) 2017 Modelled IHME
2.61 (2.33 - 2.92) 2016 Modelled IHME
2.7 (2.41 - 3.02) 2015 Modelled IHME
2.67 (2.39 - 2.99) 2014 Modelled IHME
2.71 (2.42 - 3.03) 2013 Modelled IHME
2.75 (2.47 - 3.07) 2012 Modelled IHME
2.75 (2.48 - 3.07) 2011 Modelled IHME
2.77 (2.48 - 3.08) 2010 Modelled IHME
2.81 (2.53 - 3.13) 2009 Modelled IHME
2.88 (2.58 - 3.20) 2008 Modelled IHME
2.96 (2.66 - 3.29) 2007 Modelled IHME
3.07 (2.76 - 3.41) 2006 Modelled IHME
3.19 (2.87 - 3.55) 2005 Modelled IHME
3.34 (3 - 3.69) 2004 Modelled IHME
3.57 (3.21 - 3.93) 2003 Modelled IHME
3.74 (3.39 - 4.12) 2002 Modelled IHME
3.9 (3.53 - 4.30) 2001 Modelled IHME
4.04 (3.66 - 4.46) 2000 Modelled IHME
4.13 (3.73 - 4.55) 1999 Modelled IHME
4.14 (3.75 - 4.55) 1998 Modelled IHME
4.13 (3.74 - 4.55) 1997 Modelled IHME
4.13 (3.74 - 4.56) 1996 Modelled IHME
4.18 (3.78 - 4.60) 1995 Modelled IHME
4.3 (3.88 - 4.74) 1994 Modelled IHME
4.41 (3.99 - 4.87) 1993 Modelled IHME
4.57 (4.13 - 5.04) 1992 Modelled IHME
4.83 (4.37 - 5.31) 1991 Modelled IHME
5.03 (4.55 - 5.52) 1990 Modelled IHME
Showing out of
Show more
Technical notes

HBV-related deaths

National
Download
Value Year Type Source
1,714 (1,517 - 1,927) 2019 Modelled IHME
1,676 (1,488 - 1,884) 2018 Modelled IHME
1,633 (1,451 - 1,836) 2017 Modelled IHME
1,587 (1,413 - 1,773) 2016 Modelled IHME
1,643 (1,465 - 1,834) 2015 Modelled IHME
1,626 (1,452 - 1,818) 2014 Modelled IHME
1,645 (1,474 - 1,841) 2013 Modelled IHME
1,670 (1,498 - 1,862) 2012 Modelled IHME
1,668 (1,500 - 1,860) 2011 Modelled IHME
1,669 (1,499 - 1,858) 2010 Modelled IHME
1,689 (1,518 - 1,881) 2009 Modelled IHME
1,716 (1,540 - 1,906) 2008 Modelled IHME
1,755 (1,574 - 1,946) 2007 Modelled IHME
1,805 (1,619 - 2,004) 2006 Modelled IHME
1,863 (1,673 - 2,069) 2005 Modelled IHME
1,933 (1,737 - 2,137) 2004 Modelled IHME
2,048 (1,845 - 2,257) 2003 Modelled IHME
2,138 (1,934 - 2,355) 2002 Modelled IHME
2,219 (2,008 - 2,446) 2001 Modelled IHME
2,290 (2,072 - 2,525) 2000 Modelled IHME
2,334 (2,111 - 2,572) 1999 Modelled IHME
2,336 (2,117 - 2,569) 1998 Modelled IHME
2,330 (2,109 - 2,568) 1997 Modelled IHME
2,333 (2,111 - 2,573) 1996 Modelled IHME
2,362 (2,136 - 2,600) 1995 Modelled IHME
2,432 (2,196 - 2,679) 1994 Modelled IHME
2,500 (2,261 - 2,758) 1993 Modelled IHME
2,595 (2,345 - 2,857) 1992 Modelled IHME
2,741 (2,481 - 3,012) 1991 Modelled IHME
2,854 (2,583 - 3,134) 1990 Modelled IHME
3,509 2016 Modelled WHO
Showing out of
Show more
Technical notes

Percent of liver cancer deaths attributable to HBV

National
Download
Value (%) Year Type Source
9 (8 - 11) 2019 Modelled IHME
9 (8 - 11) 2018 Modelled IHME
9 (8 - 11) 2017 Modelled IHME
9 (8 - 11) 2016 Modelled IHME
9 (8 - 10) 2015 Modelled IHME
9 (8 - 10) 2014 Modelled IHME
9 (8 - 10) 2013 Modelled IHME
9 (8 - 10) 2012 Modelled IHME
9 (8 - 10) 2011 Modelled IHME
9 (8 - 10) 2010 Modelled IHME
9 (8 - 11) 2009 Modelled IHME
9 (8 - 11) 2008 Modelled IHME
9 (8 - 11) 2007 Modelled IHME
9 (8 - 11) 2006 Modelled IHME
9 (8 - 11) 2005 Modelled IHME
10 (8 - 11) 2004 Modelled IHME
10 (8 - 12) 2003 Modelled IHME
10 (8 - 12) 2002 Modelled IHME
10 (8 - 12) 2001 Modelled IHME
10 (9 - 12) 2000 Modelled IHME
10 (9 - 13) 1999 Modelled IHME
11 (9 - 13) 1998 Modelled IHME
11 (9 - 13) 1997 Modelled IHME
11 (9 - 13) 1996 Modelled IHME
11 (9 - 13) 1995 Modelled IHME
11 (9 - 13) 1994 Modelled IHME
11 (9 - 13) 1993 Modelled IHME
11 (9 - 14) 1992 Modelled IHME
12 (10 - 14) 1991 Modelled IHME
12 (10 - 14) 1990 Modelled IHME
Showing out of
Show more
Technical notes

Coverage of 3-dose hepatitis B vaccine

Infants
Download
Value (%) Year Type Source
95 2018 Survey/reported WHO/UNICEF
94 2017 Survey/reported WHO/UNICEF
93 2016 Survey/reported WHO/UNICEF
93 2015 Survey/reported WHO/UNICEF
95 2014 Survey/reported WHO/UNICEF
96 2013 Survey/reported WHO/UNICEF
96 2012 Survey/reported WHO/UNICEF
96 2011 Survey/reported WHO/UNICEF
96 2010 Survey/reported WHO/UNICEF
96 2009 Survey/reported WHO/UNICEF
96 2008 Survey/reported WHO/UNICEF
97 2007 Survey/reported WHO/UNICEF
96 2006 Survey/reported WHO/UNICEF
96 2005 Survey/reported WHO/UNICEF
96 2004 Survey/reported WHO/UNICEF
95 2003 Survey/reported WHO/UNICEF
95 2002 Survey/reported WHO/UNICEF
95 2001 Survey/reported WHO/UNICEF
94 2000 Survey/reported WHO/UNICEF
97 1999 Survey/reported WHO/UNICEF
95 1998 Survey/reported WHO/UNICEF
95 1997 Survey/reported WHO/UNICEF
95 1996 Survey/reported WHO/UNICEF
95 1995 Survey/reported WHO/UNICEF
95 1994 Survey/reported WHO/UNICEF
95 1993 Survey/reported WHO/UNICEF
95 1992 Survey/reported WHO/UNICEF
95 1991 Survey/reported WHO/UNICEF
Showing out of
Show more

Percent of PWID accessing OST

People who inject drugs (PWID)
Download
Value (%) Year Type Source
30 2017 Survey/reported EMCDDA, 2019
HBV National Action Plan
HBV elimination goal
HepB birth dose policy
Yes (for risk groups)
Source: WHO
Eligible for HBV generic medicines
Source: MPP
HCV National Action Plan
HCV elimination goal
Eligible for HCV generic medicines
Source: MPP
At least one needle-syringe exchange program (NSP) operational
Yes
Source: Harm Reduction International
At least one opioid substitution therapy (OST) program operational
Yes
Source: Harm Reduction International
NSP in at least one prison
No
Source: Harm Reduction International
OST in at least one prison
Yes
Source: Harm Reduction International
% of substance use disorder facilities offering hepatitis testing
Many (31-60%)
Source: WHO
% of substance use disorder facilities offering hepatitis treatment
Some (11-30%)
Source: WHO

Hepatitis C

Download HCV data

Prevalence of chronic HCV (RNA+/cAg)

National
Download
Value (%) Year Type Source
1.78 (1.44 - 2.19) 2019 Modelled IHME
1.77 (1.44 - 2.18) 2018 Modelled IHME
1.76 (1.42 - 2.16) 2017 Modelled IHME
1.72 (1.39 - 2.11) 2016 Modelled IHME
1.7 (1.37 - 2.07) 2015 Modelled IHME
1.72 (1.39 - 2.10) 2014 Modelled IHME
1.78 (1.44 - 2.18) 2013 Modelled IHME
1.86 (1.51 - 2.28) 2012 Modelled IHME
1.93 (1.56 - 2.35) 2011 Modelled IHME
1.96 (1.59 - 2.39) 2010 Modelled IHME
1.96 (1.60 - 2.39) 2009 Modelled IHME
1.96 (1.60 - 2.39) 2008 Modelled IHME
1.97 (1.60 - 2.39) 2007 Modelled IHME
1.97 (1.61 - 2.39) 2006 Modelled IHME
1.97 (1.61 - 2.39) 2005 Modelled IHME
2.02 (1.65 - 2.44) 2004 Modelled IHME
2.11 (1.73 - 2.55) 2003 Modelled IHME
2.22 (1.81 - 2.68) 2002 Modelled IHME
2.32 (1.89 - 2.80) 2001 Modelled IHME
2.35 (1.92 - 2.84) 2000 Modelled IHME
2.35 (1.92 - 2.84) 1999 Modelled IHME
2.35 (1.91 - 2.83) 1998 Modelled IHME
2.34 (1.91 - 2.83) 1997 Modelled IHME
2.33 (1.90 - 2.82) 1996 Modelled IHME
2.32 (1.89 - 2.81) 1995 Modelled IHME
2.29 (1.87 - 2.77) 1994 Modelled IHME
2.22 (1.82 - 2.69) 1993 Modelled IHME
2.13 (1.74 - 2.58) 1992 Modelled IHME
2.03 (1.65 - 2.46) 1991 Modelled IHME
1.91 (1.56 - 2.32) 1990 Modelled IHME
Showing out of
Show more

Prevalence of anti-HCV

National
Download
Value (%) Year Type Source
5.9 (5.20 - 6.60) 2016 Modelled ECDC
3 (2.20 - 4.10) 2014 Survey/reported Morisco, 2017
2.6 (2 - 3.40) 2007 Survey/reported Cozzolongo R et al, 2009
6.5 (5.40 - 7.80) 2003 Survey/reported Pendino GM, 2005
10.2 (8 - 12.70) 2001 Survey/reported Floreani A, 2006
2 (1.60 - 7.30) 2014 Modelled Gower et al, 2014
Showing out of
Show more
People who inject drugs (PWID)
Download
Value (%) Year Type Source
57.9 (52.50 - 63.30) 2014 Modelled Degenhardt L et al, 2017
60.5 (56.80 - 64) 2010 Survey/reported EMCDDA
Showing out of
Show more
Pregnant women
Download
Value (%) Year Type Source
0.4 (0.30 - 0.50) 2012 Survey/reported Ruffini E et al, 2014
Prisoners
Download
Value (%) Year Type Source
38 (35 - 41.20) 2002 Survey/reported Babudieri S et al, 2005

HCV-related death rate

National
Download
Value (per 100,000) Year Type Source
13.3 (11.80 - 14.70) 2019 Modelled IHME
13.1 (11.60 - 14.30) 2018 Modelled IHME
12.7 (11.30 - 14) 2017 Modelled IHME
12.4 (11 - 13.60) 2016 Modelled IHME
12.9 (11.40 - 14.10) 2015 Modelled IHME
12.7 (11.30 - 13.90) 2014 Modelled IHME
12.9 (11.50 - 14.10) 2013 Modelled IHME
13 (11.60 - 14.20) 2012 Modelled IHME
13 (11.60 - 14.20) 2011 Modelled IHME
12.9 (11.50 - 14) 2010 Modelled IHME
12.8 (11.50 - 14) 2009 Modelled IHME
12.7 (11.40 - 13.90) 2008 Modelled IHME
12.6 (11.40 - 13.80) 2007 Modelled IHME
12.7 (11.40 - 13.90) 2006 Modelled IHME
12.8 (11.60 - 14) 2005 Modelled IHME
13.2 (11.90 - 14.40) 2004 Modelled IHME
13.8 (12.60 - 14.90) 2003 Modelled IHME
14.3 (13.10 - 15.50) 2002 Modelled IHME
14.6 (13.50 - 15.80) 2001 Modelled IHME
15 (13.80 - 16.20) 2000 Modelled IHME
15.3 (14.10 - 16.50) 1999 Modelled IHME
15.4 (14.20 - 16.70) 1998 Modelled IHME
15.5 (14.30 - 16.80) 1997 Modelled IHME
15.7 (14.50 - 17) 1996 Modelled IHME
15.8 (14.60 - 17.10) 1995 Modelled IHME
16.1 (14.80 - 17.30) 1994 Modelled IHME
16 (14.70 - 17.23) 1993 Modelled IHME
15.8 (14.50 - 17) 1992 Modelled IHME
15.7 (14.40 - 16.90) 1991 Modelled IHME
15.4 (14.20 - 16.60) 1990 Modelled IHME
Showing out of
Show more
Technical notes

HCV-related deaths

National
Download
Value Year Type Source
8,050 (7,096 - 8,856) 2019 Modelled IHME
7,905 (7,007 - 8,662) 2018 Modelled IHME
7,719 (6,858 - 8,483) 2017 Modelled IHME
7,523 (6,682 - 8,238) 2016 Modelled IHME
7,811 (6,923 - 8,542) 2015 Modelled IHME
7,748 (6,896 - 8,468) 2014 Modelled IHME
7,816 (6,969 - 8,542) 2013 Modelled IHME
7,919 (7,057 - 8,637) 2012 Modelled IHME
7,861 (7,027 - 8,576) 2011 Modelled IHME
7,772 (6,962 - 8,476) 2010 Modelled IHME
7,709 (6,897 - 8,410) 2009 Modelled IHME
7,596 (6,822 - 8,292) 2008 Modelled IHME
7,477 (6,734 - 8,167) 2007 Modelled IHME
7,436 (6,715 - 8,140) 2006 Modelled IHME
7,486 (6,767 - 8,179) 2005 Modelled IHME
7,614 (6,909 - 8,313) 2004 Modelled IHME
7,904 (7,211 - 8,568) 2003 Modelled IHME
8,149 (7,465 - 8,829) 2002 Modelled IHME
8,318 (7,651 - 8,992) 2001 Modelled IHME
8,485 (7,839 - 9,180) 2000 Modelled IHME
8,644 (7,994 - 9,338) 1999 Modelled IHME
8,703 (8,043 - 9,427) 1998 Modelled IHME
8,768 (8,078 - 9,466) 1997 Modelled IHME
8,857 (8,161 - 9,577) 1996 Modelled IHME
8,950 (8,257 - 9,679) 1995 Modelled IHME
9,097 (8,384 - 9,798) 1994 Modelled IHME
9,036 (8,315 - 9,759) 1993 Modelled IHME
8,945 (8,204 - 9,662) 1992 Modelled IHME
8,894 (8,187 - 9,612) 1991 Modelled IHME
8,734 (8,050 - 9,446) 1990 Modelled IHME
10,470 2016 Modelled WHO
Showing out of
Show more
Technical notes

Percent of liver cancer deaths attributable to HCV

National
Download
Value (%) Year Type Source
58 (54 - 62) 2019 Modelled IHME
58 (54 - 62) 2018 Modelled IHME
58 (54 - 62) 2017 Modelled IHME
57 (53 - 61) 2016 Modelled IHME
57 (53 - 61) 2015 Modelled IHME
57 (53 - 61) 2014 Modelled IHME
57 (53 - 61) 2013 Modelled IHME
57 (53 - 61) 2012 Modelled IHME
57 (53 - 61) 2011 Modelled IHME
57 (53 - 61) 2010 Modelled IHME
57 (53 - 61) 2009 Modelled IHME
57 (53 - 61) 2008 Modelled IHME
57 (53 - 61) 2007 Modelled IHME
57 (53 - 60) 2006 Modelled IHME
56 (52 - 60) 2005 Modelled IHME
56 (52 - 60) 2004 Modelled IHME
56 (52 - 60) 2003 Modelled IHME
55 (51 - 60) 2002 Modelled IHME
55 (51 - 59) 2001 Modelled IHME
55 (51 - 59) 2000 Modelled IHME
54 (50 - 59) 1999 Modelled IHME
54 (50 - 59) 1998 Modelled IHME
55 (50 - 59) 1997 Modelled IHME
55 (50 - 59) 1996 Modelled IHME
54 (50 - 59) 1995 Modelled IHME
54 (50 - 59) 1994 Modelled IHME
54 (50 - 58) 1993 Modelled IHME
54 (50 - 58) 1992 Modelled IHME
54 (50 - 58) 1991 Modelled IHME
54 (49 - 58) 1990 Modelled IHME
Showing out of
Show more
Technical notes

Percent of PWID accessing OST

People who inject drugs (PWID)
Download
Value (%) Year Type Source
30 2017 Survey/reported EMCDDA, 2019
HBV National Action Plan
HBV elimination goal
HepB birth dose policy
Yes (for risk groups)
Source: WHO
Eligible for HBV generic medicines
Source: MPP
HCV National Action Plan
HCV elimination goal
Eligible for HCV generic medicines
Source: MPP
At least one needle-syringe exchange program (NSP) operational
Yes
Source: Harm Reduction International
At least one opioid substitution therapy (OST) program operational
Yes
Source: Harm Reduction International
NSP in at least one prison
No
Source: Harm Reduction International
OST in at least one prison
Yes
Source: Harm Reduction International
% of substance use disorder facilities offering hepatitis testing
Many (31-60%)
Source: WHO
% of substance use disorder facilities offering hepatitis treatment
Some (11-30%)
Source: WHO

Overview

HBV elimination goal
HCV elimination goal

Prevalence (national)

Modelled

HBV (HBsAg+)
0.71 (%)
2019
(0.62 - 0.8(%))
IHME
HCV (RNA/cAg+)
1.78 (%)
2019
(1.44 - 2.19(%))
IHME

Survey/surveillance

HBV (HBsAg+)
1.7 (%)
2014
(0.9 - 2.9(%))
Morisco, 2017
HCV (anti-HCV)
3 (%)
2014
(2.2 - 4.1(%))
Morisco, 2017

Hepatitis related deaths (national)

Modelled

HBV
1,714
2019
(1,517 - 1,927)
IHME

Survey/surveillance

No data available
HBV chart

Modelled

HCV
8,050
2019
(7,096 - 8,856)
IHME

Survey/surveillance

No data available
HCV chart

Prevalence < 5

HBV
0.03 (%)
2019, latest modelled
(0.02 - 0.03(%))
IHME

Prevalence PWID

HCV
60.50 (%)
2010, survey/surveillance
(56.80 - 64(%))
EMCDDA

Birth dose vaccination coverage (national)

Survey/surveillance

No data available

No. of syringes/PWID/year

Survey/surveillance

No data available
Eligible for HBV generic medicines
Eligible for HCV generic medicines

Resources